Clinical trial
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic…
NCT00398086 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00398086 |
|---|---|
| Title | Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer |
| Official title | A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (ABRAXANE) In Patients With Advanced Metastatic Pancreatic Cancer |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Albumin-bound paclitaxel |
| Enrollment | 67 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Dec 1, 2010 |
| First posted | Nov 10, 2006 |
| Last update posted | Nov 22, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: